<?xml version='1.0' encoding='utf-8'?>
<document id="21778352"><sentence text="Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses."><entity charOffset="35-46" id="DDI-PubMed.21778352.s1.e0" text="gemfibrozil" /><entity charOffset="51-62" id="DDI-PubMed.21778352.s1.e1" text="repaglinide" /><entity charOffset="122-133" id="DDI-PubMed.21778352.s1.e2" text="gemfibrozil" /><pair ddi="false" e1="DDI-PubMed.21778352.s1.e0" e2="DDI-PubMed.21778352.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21778352.s1.e0" e2="DDI-PubMed.21778352.s1.e1" /><pair ddi="false" e1="DDI-PubMed.21778352.s1.e0" e2="DDI-PubMed.21778352.s1.e2" /><pair ddi="false" e1="DDI-PubMed.21778352.s1.e1" e2="DDI-PubMed.21778352.s1.e1" /><pair ddi="false" e1="DDI-PubMed.21778352.s1.e1" e2="DDI-PubMed.21778352.s1.e2" /></sentence><sentence text="Gemfibrozil 1-O-β-glucuronide inactivates CYP2C8 irreversibly"><entity charOffset="0-29" id="DDI-PubMed.21778352.s2.e0" text="Gemfibrozil 1-O-β-glucuronide" /></sentence><sentence text=" We investigated the effect of gemfibrozil dose on CYP2C8 activity in humans using repaglinide as a probe drug"><entity charOffset="31-42" id="DDI-PubMed.21778352.s3.e0" text="gemfibrozil" /><entity charOffset="83-94" id="DDI-PubMed.21778352.s3.e1" text="repaglinide" /><pair ddi="false" e1="DDI-PubMed.21778352.s3.e0" e2="DDI-PubMed.21778352.s3.e0" /><pair ddi="false" e1="DDI-PubMed.21778352.s3.e0" e2="DDI-PubMed.21778352.s3.e1" /></sentence><sentence text=" In a randomized, five-phase crossover study, 10 healthy volunteers ingested 0" /><sentence text="25 mg of repaglinide 1 h after different doses of gemfibrozil or placebo"><entity charOffset="9-20" id="DDI-PubMed.21778352.s5.e0" text="repaglinide" /><entity charOffset="50-61" id="DDI-PubMed.21778352.s5.e1" text="gemfibrozil" /><pair ddi="false" e1="DDI-PubMed.21778352.s5.e0" e2="DDI-PubMed.21778352.s5.e0" /><pair ddi="false" e1="DDI-PubMed.21778352.s5.e0" e2="DDI-PubMed.21778352.s5.e1" /></sentence><sentence text=" Concentrations of plasma repaglinide, gemfibrozil, their metabolites, and blood glucose were measured"><entity charOffset="26-37" id="DDI-PubMed.21778352.s6.e0" text="repaglinide" /><entity charOffset="39-50" id="DDI-PubMed.21778352.s6.e1" text="gemfibrozil" /><entity charOffset="81-88" id="DDI-PubMed.21778352.s6.e2" text="glucose" /><pair ddi="false" e1="DDI-PubMed.21778352.s6.e0" e2="DDI-PubMed.21778352.s6.e0" /><pair ddi="false" e1="DDI-PubMed.21778352.s6.e0" e2="DDI-PubMed.21778352.s6.e1" /><pair ddi="false" e1="DDI-PubMed.21778352.s6.e0" e2="DDI-PubMed.21778352.s6.e2" /><pair ddi="false" e1="DDI-PubMed.21778352.s6.e1" e2="DDI-PubMed.21778352.s6.e1" /><pair ddi="false" e1="DDI-PubMed.21778352.s6.e1" e2="DDI-PubMed.21778352.s6.e2" /></sentence><sentence text=" A single gemfibrozil dose of 30, 100, 300, and 900 mg increased the area under the concentration-time curve of repaglinide 1"><entity charOffset="10-21" id="DDI-PubMed.21778352.s7.e0" text="gemfibrozil" /><entity charOffset="112-123" id="DDI-PubMed.21778352.s7.e1" text="repaglinide" /><pair ddi="false" e1="DDI-PubMed.21778352.s7.e0" e2="DDI-PubMed.21778352.s7.e0" /><pair ddi="false" e1="DDI-PubMed.21778352.s7.e0" e2="DDI-PubMed.21778352.s7.e1" /></sentence><sentence text="8-, 4" /><sentence text="5-, 6" /><sentence text="7-, and 8" /><sentence text="3-fold (P &lt; 0" /><sentence text="001), and its peak concentration 1" /><sentence text="4-, 1" /><sentence text="7-, 2" /><sentence text="1-, and 2" /><sentence text="4-fold (P &lt; 0" /><sentence text="05), compared with placebo, respectively" /><sentence text=" Gemfibrozil pharmacokinetics was characterized by a slightly more than dose-proportional increase in the area under the curve of gemfibrozil and its glucuronide"><entity charOffset="1-12" id="DDI-PubMed.21778352.s18.e0" text="Gemfibrozil" /><entity charOffset="130-141" id="DDI-PubMed.21778352.s18.e1" text="gemfibrozil" /><entity charOffset="150-161" id="DDI-PubMed.21778352.s18.e2" text="glucuronide" /><pair ddi="false" e1="DDI-PubMed.21778352.s18.e0" e2="DDI-PubMed.21778352.s18.e0" /><pair ddi="false" e1="DDI-PubMed.21778352.s18.e0" e2="DDI-PubMed.21778352.s18.e1" /><pair ddi="false" e1="DDI-PubMed.21778352.s18.e0" e2="DDI-PubMed.21778352.s18.e2" /><pair ddi="false" e1="DDI-PubMed.21778352.s18.e1" e2="DDI-PubMed.21778352.s18.e1" /><pair ddi="false" e1="DDI-PubMed.21778352.s18.e1" e2="DDI-PubMed.21778352.s18.e2" /></sentence><sentence text=" The gemfibrozil-repaglinide interaction could be mainly explained by gemfibrozil 1-O-β-glucuronide concentration-dependent, mechanism-based inhibition of CYP2C8, with a minor contribution by competitive inhibition of organic anion-transporting polypeptide 1B1 at the highest gemfibrozil dose"><entity charOffset="5-16" id="DDI-PubMed.21778352.s19.e0" text="gemfibrozil" /><entity charOffset="70-99" id="DDI-PubMed.21778352.s19.e1" text="gemfibrozil 1-O-β-glucuronide" /><entity charOffset="276-287" id="DDI-PubMed.21778352.s19.e2" text="gemfibrozil" /><pair ddi="false" e1="DDI-PubMed.21778352.s19.e0" e2="DDI-PubMed.21778352.s19.e0" /><pair ddi="false" e1="DDI-PubMed.21778352.s19.e0" e2="DDI-PubMed.21778352.s19.e1" /><pair ddi="false" e1="DDI-PubMed.21778352.s19.e0" e2="DDI-PubMed.21778352.s19.e2" /><pair ddi="false" e1="DDI-PubMed.21778352.s19.e1" e2="DDI-PubMed.21778352.s19.e1" /><pair ddi="false" e1="DDI-PubMed.21778352.s19.e1" e2="DDI-PubMed.21778352.s19.e2" /></sentence><sentence text=" The findings are consistent with ∼50% inhibition of CYP2C8 already with a single 30-mg dose of gemfibrozil and &gt;95% inhibition with 900 mg"><entity charOffset="96-107" id="DDI-PubMed.21778352.s20.e0" text="gemfibrozil" /></sentence><sentence text=" In clinical drug-drug interaction studies, a single 900-mg dose of gemfibrozil can be used to achieve nearly complete inactivation of CYP2C8"><entity charOffset="68-79" id="DDI-PubMed.21778352.s21.e0" text="gemfibrozil" /></sentence><sentence text="" /></document>